Alliancebernstein L.P. Nuvalent, Inc. Transaction History
Alliancebernstein L.P.
- $287 Billion
- Q3 2024
A detailed history of Alliancebernstein L.P. transactions in Nuvalent, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 39,120 shares of NUVL stock, worth $3.36 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,120
Previous 39,120
-0.0%
Holding current value
$3.36 Million
Previous $2.97 Million
34.85%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding NUVL
# of Institutions
211Shares Held
59.5MCall Options Held
450KPut Options Held
619K-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.72 Billion38.02% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5MShares$429 Million18.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.13MShares$355 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$259 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.98MShares$256 Million7.96% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.69B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...